Workflow
Compass Therapeutics(CMPX) - 2024 Q1 - Quarterly Results

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update Enrollment is progressing well in COMPANION-002, a Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Enrollment is expected to be completed by mid-year 2024 with top-line data expected in the first quarter of 2025. Advanced CTX-8371 (PD-1 x PD-L1 bispecific antibody) into a first-in-human clinical study and dosed the first patient in Ap ...